GH Research PLC (GHRS)
GHRS Stock Price Chart
Explore GH Research PLC interactive price chart. Choose custom timeframes to analyze GHRS price movements and trends.
GHRS Company Profile
Discover essential business fundamentals and corporate details for GH Research PLC (GHRS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Jun 2021
Employees
50.00
Website
https://www.ghres.comCEO
Velichka Valcheva
Description
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
GHRS Financial Timeline
Browse a chronological timeline of GH Research PLC corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.31.
Earnings released on 14 May 2026
EPS came in at -$0.31 falling short of the estimated -$0.27 by -14.81%.
Earnings released on 5 Mar 2026
EPS came in at -$0.23 surpassing the estimated -$0.29 by +20.69%.
Earnings released on 6 Nov 2025
EPS came in at -$0.23 matching the estimated -$0.23.
Earnings released on 7 Aug 2025
EPS came in at -$0.15 surpassing the estimated -$0.22 by +31.82%.
Earnings released on 8 May 2025
EPS came in at -$0.19 surpassing the estimated -$0.61 by +68.85%.
Earnings released on 27 Feb 2025
EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%.
Earnings released on 14 Nov 2024
EPS came in at -$0.23 surpassing the estimated -$0.25 by +8.00%.
Earnings released on 3 Sept 2024
EPS came in at -$0.20 surpassing the estimated -$0.23 by +13.04%.
Earnings released on 3 May 2024
EPS came in at -$0.15 surpassing the estimated -$0.22 by +31.82%.
Earnings released on 29 Feb 2024
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%.
Earnings released on 9 Nov 2023
EPS came in at -$0.11 surpassing the estimated -$0.20 by +45.00%.
Earnings released on 23 Aug 2023
EPS came in at -$0.15 surpassing the estimated -$0.25 by +40.00%.
Earnings released on 11 May 2023
EPS came in at -$0.21 surpassing the estimated -$0.22 by +4.55%.
Earnings released on 2 Mar 2023
EPS came in at -$0.32 falling short of the estimated -$0.17 by -88.24%.
Earnings released on 10 Nov 2022
EPS came in at -$0.01 surpassing the estimated -$0.17 by +94.12%.
Earnings released on 23 Aug 2022
EPS came in at -$0.12 surpassing the estimated -$0.17 by +29.41%.
Earnings released on 18 May 2022
EPS came in at -$0.11 surpassing the estimated -$0.16 by +31.25%.
Earnings released on 28 Mar 2022
EPS came in at -$0.09 surpassing the estimated -$0.17 by +47.06%.
Earnings released on 6 Dec 2021
EPS came in at -$0.04 surpassing the estimated -$0.10 by +60.00%.
Earnings released on 23 Sept 2021
EPS came in at -$0.05 surpassing the estimated -$0.08 by +37.50%.
GHRS Stock Performance
Access detailed GHRS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
